An interventional study of RT-CGM and SMBG in Type 2 Diabetes Mellitus (T2DM), sponsored by Shanghai 6th People's Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 10th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai 6th People's Hospital · Sites in China
Ages 35–70
Shanghai 6th People's Hospital · Sites in China
Ages 18–70
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 60+
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 150 across the 8 interventional studies, 225 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai 6th People's Hospital is the lead sponsor of 70 studies on the registry; 39 are open to participants now.
5 of the studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007676Shanghai 6th People's HospitalEffect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes | 2027-02-28 |
| NCT06936657Shanghai 6th People's HospitalIntervention Effects of Optimized Carbohydrate Diet in Patients With Type 2 Diabetes | 2027-06-30 |
| NCT07288372Shanghai 6th People's HospitalThe CGM-OGTT Glycemic Homeostasis Study | 2027-06-30 |
| NCT07156370Shanghai 6th People's HospitalSalivary Cortisol and Hypercortisolism in Type 2 Diabetes | 2027-06-30 |
| NCT07414277Shanghai 6th People's HospitalCGM for Insulin-Treated T2DM During Post-Discharge Transition | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.
A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will use a Real-Time Continuous Glucose Monitoring (RT-CGM) system intermittently during the 12-week intervention period, followed by a 14-week follow-up period.
Device: RT-CGM
Participants in this group will perform standard Self-Monitoring of Blood Glucose (SMBG) using a blood glucose meter throughout the 12-week intervention period, followed by a 14-week follow-up period.
Device: SMBG
RT-CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
SMBG provides discrete, point-in-time capillary blood glucose measurements via fingerstick testing.
Difference between change in HbA1c between the intervention group and the control group at Week 12
HbA1c, expressed as %
Time frame: from baseline to Week 12
Difference between change in HbA1c between the intervention group and the control group at Week 24
HbA1c, expressed as %
Time frame: from baseline to Week 24
Difference in CGM Time in Range (TIR) (3.9-10.0 mmol/L) between the intervention group and the control group at Week 14 and Week 26
Percent
Time frame: at Week 14 and Week 26
Difference in CGM Time Above Range (TAR) (>10.0 mmol/L; >13.9 mmol/L) between the intervention group and the control group at Week 14 and Week 26
Percent
Time frame: at Week 14 and Week 26
Difference in CGM Time Below Range (TBR) (<3.9 mmol/L; <3.0 mmol/L) between the intervention group and the control group at Week 14 and Week 26
percent
Time frame: at Week 14 and Week 26
Difference in CGM coefficient of variation (CV) between the intervention group and the control group at Week 14 and Week 26
percent
Time frame: at Week 14 and Week 26
Difference between change in self-efficacy score between the intervention group and the control group at Week 12 and Week 24
Measured by Diabetes Management Self-efficacy Scale (DMSES) ;Total score ranges from 0 to 200 (0 to 10 per item across 20 items);Higher scores mean: A better outcome (indicating higher self-efficacy in managing diabetes).
Time frame: from baseline to Week 12 and Week 24
Difference between change in diabetes-related distress between the intervention group and the control group at Week 12 and Week 24
Measured by the Diabetes Distress Scale (DDS);Total score ranges from 17 to 102 (1 to 6 per item across 17 items);Higher scores mean: A worse outcome (indicating higher levels of diabetes-related distress).
Time frame: from baseline to Week 12 and Week 24
Difference between change in glucose monitoring satisfaction between the intervention group and the control group at Week 12
Measured by the Glucose Monitoring Satisfaction Scale (GMSS), Version: Type 2 Diabetes;Total score ranges from 15 to 75 (1 to 5 per item across 15 items);Higher scores mean: A better outcome (indicating higher satisfaction with glucose monitoring).
Time frame: from baseline to Week 12 and Week 24
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 16 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai 6th People's Hospital